Glycemic Control Improves with Fast-Acting Insulin Aspart in T1D

Researchers examined the efficacy and safety of fast-acting insulin aspart for glycemic control in type 1 diabetes.
Researchers examined the efficacy and safety of fast-acting insulin aspart for glycemic control in type 1 diabetes.

HealthDay News — Fast-acting insulin aspart improves glycemic control in type 1 diabetes, according to a study published online in Diabetes Care.

David Russell-Jones, MBBS, MD, from the Royal Surrey Country Hospital in Guildford, UK, and colleagues examined the efficacy and safety of fast-acting insulin aspart (faster aspart) versus conventional insulin aspart (IAsp) in a multicenter phase 3 trial. Adults with type 1 diabetes were randomized to either double-blind mealtime faster aspart (381 adults), IAsp (380 adults), or open-label postmeal faster aspart (382 adults).

The researchers found that in both treatment groups, hemoglobin A1c (HbA1c) was reduced, and noninferiority to IAsp was confirmed for both mealtime and postmeal faster aspart (estimated treatment difference: mealtime, -0.15%; postmeal, 0.04%). There was a statistically significant reduction in HbA1c for mealtime faster aspart versus IAsp (P =.0003). At 1 hour and 2 hours after the meal test, postprandial plasma glucose (PPG) increments were statistically significantly lower with mealtime faster aspart (estimated treatment difference, -1.18 mmol/L and -0.67 mmol/L, respectively); for the 2-hour PPG increment, superiority to IAsp was confirmed. Between treatments, the overall rate of severe or blood glucose-confirmed hypoglycemic episodes and safety profiles were similar.

"Faster aspart effectively improved HbA1c, and noninferiority to IAsp was confirmed, with superior PPG control for mealtime faster aspart versus IAsp," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Novo Nordisk, which funded the study.

Reference

Russel-Jones D, Bode BW, De Block C, et al. Fast-acting insulin aspart improves glycemic control in basal-blous treatment for type 1 diabetes: results of a 26-week multicenter, active-controlled, treat-to-target, randomized, parallel-group trial (Onset 1) [published online April 2017]. Diabetes Care. doi: 10.2337/dc16-1771

You must be a registered member of Endocrinology Advisor to post a comment.

Sign Up for Free e-Newsletters